Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks and strokes in survivors.

ANSWER: “Floaters” are bits of cellular debris in the vitreous humor, which is the gel-filled space in between the lens and ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.